A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-06-01
DOI
10.1038/s41388-023-02737-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
- (2023) María Jimena Rodriguez et al. Scientific Reports
- Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors
- (2022) G. Leslie Burnett et al. Journal of Medicinal Chemistry
- Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
- (2021) Chao Dong et al. Frontiers in Pharmacology
- Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
- (2021) Bianca J. Lee et al. Nature Chemical Biology
- Split-personality inhibitors
- (2021) Carson C. Thoreen Nature Chemical Biology
- Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
- (2021) Erin R. Scheidemann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Saga of Mcl-1: regulation from transcription to degradation
- (2020) Viacheslav V. Senichkin et al. CELL DEATH AND DIFFERENTIATION
- The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer
- (2020) Seth A. Wander et al. Cancer Discovery
- Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications
- (2020) Giulia Occhipinti et al. Frontiers in Genetics
- Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
- (2020) Jackie E. Bader et al. MOLECULAR CELL
- MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
- (2019) Liam Cornell et al. Cell Reports
- SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
- (2019) Akihiro Yoshida et al. Science Advances
- Efficacy of PI3K inhibitors in advanced breast cancer
- (2019) B Verret et al. ANNALS OF ONCOLOGY
- PI3K inhibition to overcome endocrine resistance in breast cancer
- (2018) Niamh M Keegan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
- (2018) Chrysiis Michaloglou et al. MOLECULAR CANCER THERAPEUTICS
- Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming
- (2017) Phillip A. Geter et al. GENES & DEVELOPMENT
- Transcriptome-wide measurement of translation by ribosome profiling
- (2017) Nicholas J. McGlincy et al. METHODS
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Synergistic interactions with PI3K inhibition that induce apoptosis
- (2017) Yaara Zwang et al. eLife
- PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
- (2016) Angel Guerrero-Zotano et al. CANCER AND METASTASIS REVIEWS
- Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
- (2016) John F R Robertson et al. LANCET
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Bivalent mTOR inhibitors — the next generation
- (2016) Alexandra Flemming NATURE REVIEWS DRUG DISCOVERY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c
- (2012) Asami Hagiwara et al. Cell Metabolism
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1 promotes survival through translational control of Mcl-1
- (2008) J. R. Mills et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search